AR080692A1 - Compuestos, composiciones y metodos para la administracion no toxica de antiprogestinas - Google Patents

Compuestos, composiciones y metodos para la administracion no toxica de antiprogestinas

Info

Publication number
AR080692A1
AR080692A1 ARP110100899A ARP110100899A AR080692A1 AR 080692 A1 AR080692 A1 AR 080692A1 AR P110100899 A ARP110100899 A AR P110100899A AR P110100899 A ARP110100899 A AR P110100899A AR 080692 A1 AR080692 A1 AR 080692A1
Authority
AR
Argentina
Prior art keywords
alkyl
acyl
alkoxy
hydrogen
group
Prior art date
Application number
ARP110100899A
Other languages
English (en)
Inventor
Ronald D Wiehle
Joseph S Podolski
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44343114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR080692(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of AR080692A1 publication Critical patent/AR080692A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El objeto es pertinente para el campo del tratamiento de las afecciones dependientes de hormonas. Se divulgan compuestos y métodos para tratar estas afecciones. Se divulgan métodos para tratar la endometriosis, la dismenorrea, el cáncer del seno, los fibromas uterinos y la hiperproliferacion endometrial. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula general (1) o una sal aceptable desde el punto de vista farmacéutico de este, donde R1 se selecciona del grupo que incluye: alquilo; alquenilo; cicloalquilo; cicloalquenilo; arilo; H; CH3SO; CH3SO2 acilo; alcoxi; tioalcoxi; tioalquilo, aciloxi; Si(CH3)3; el resto de formula (2) donde X e Y son acilo; aziridinilo, azirinilo, azetidinilo, pirrolidinilo, etoxipirrolidinilo, metoxipirrolidinilo, piperidinilo, etoxipiperidinilo, morfolinilo, etoximorfolinilo, oxazinilo, piperazinilo, metilpiperazinilo, etilpiperazinilo y diazinilo; R2 se selecciona del grupo que incluye: hidrogeno, halogeno, alquilo, acilo, hidroxilo, alcoxi, aciloxi, carbonato de alquilo, cipioniloxi, S-alquilo, S-CN, S-acilo y -OC(O)R6 donde R6 es alquilo, alcoxialquilo o alcoxi; R3 se selecciona del grupo que incluye: alquilo, hidroxi, alcoxi y aciloxi con la condicion de que sea distinto de acetoxi o propinilo; R4 es hidrogeno o alquilo; y X se selecciona del grupo que incluye: =O, N-OR5 donde R5 es hidrogeno o alquilo, OH, CH2, OAIk1 y OCOAlk2, donde Alk1 y Alk2 son alquilo C1-8 o aralalquilo C7-15, con la condicion de que si R1 está en la posicion para y es -OCH3, -SCH3, -NC4H8, -NC5H10, -NC4H8O, -CHO, -CH(OH)CH3, -COCH3, -O(CH2)2NC4H8 o -O(CH2)2NC5H10, X sea distinto de =O o =N-OR5, donde R5 es hidrogeno o alquilo.
ARP110100899A 2010-03-22 2011-03-18 Compuestos, composiciones y metodos para la administracion no toxica de antiprogestinas AR080692A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31626310P 2010-03-22 2010-03-22

Publications (1)

Publication Number Publication Date
AR080692A1 true AR080692A1 (es) 2012-05-02

Family

ID=44343114

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100899A AR080692A1 (es) 2010-03-22 2011-03-18 Compuestos, composiciones y metodos para la administracion no toxica de antiprogestinas

Country Status (24)

Country Link
US (3) US20130018027A1 (es)
EP (2) EP3865502A1 (es)
JP (4) JP5894143B2 (es)
KR (2) KR20130009990A (es)
CN (3) CN107260746A (es)
AR (1) AR080692A1 (es)
AU (4) AU2010348967C1 (es)
BR (2) BR112012023281A2 (es)
CA (1) CA2793712A1 (es)
CL (1) CL2012002544A1 (es)
CO (1) CO6602170A2 (es)
CR (1) CR20120514A (es)
EA (1) EA023743B1 (es)
EC (1) ECSP12012226A (es)
IL (2) IL221820B (es)
MX (1) MX2012010327A (es)
MY (1) MY164622A (es)
NI (2) NI201200142A (es)
NZ (1) NZ602525A (es)
SG (3) SG183924A1 (es)
TW (1) TWI581797B (es)
UA (1) UA110030C2 (es)
WO (1) WO2011119194A1 (es)
ZA (1) ZA201207688B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10064815B2 (en) * 2014-05-05 2018-09-04 Repros Therapeutics Inc. Formulations and methods for vaginal delivery of antiprogestins
RU2017112748A (ru) 2014-11-17 2018-12-19 Арно Терапьютикс, Инк. Композиции онапристона пролонгированного действия и способы
EP3353148A4 (en) 2015-09-25 2019-04-24 Context Biopharma Inc. PROCESS FOR THE PRODUCTION OF ONAPRISTONE INTERMEDIATE PRODUCTS
AU2016370499B2 (en) 2015-12-15 2022-06-30 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
AU2017223595B2 (en) * 2016-02-24 2022-11-24 Eastern Virginia Medical School An improved formulation of long-acting levonorgestrel butanoate injectable depot suspension
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
EP0116974B1 (de) 1983-02-18 1986-10-29 Schering Aktiengesellschaft 11-Beta-Aryl-Estradiene, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
EP0501523B1 (en) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3506785A1 (de) 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2598421B1 (fr) * 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
US5446178A (en) 1987-03-18 1995-08-29 Schering Aktiengesellschaft Process for preparing 19,11β-bridged steroids
DE3866410D1 (de) 1987-04-24 1992-01-09 Akzo Nv 11-arylestranderivate und 11-arylpregnanderivate.
ES2053714T3 (es) 1987-12-12 1994-08-01 Akzo Nv Proceso para la preparacion de 11-arilesteroides.
DE3820948A1 (de) 1988-06-16 1989-12-21 Schering Ag 10ss, 11ss-ueberbrueckte steroide
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
DE3822770A1 (de) 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
DE3832303A1 (de) 1988-09-20 1990-04-12 Schering Ag 11ss-phenyl-14ssh-steroide
DE3917274A1 (de) 1989-05-24 1990-11-29 Schering Ag 9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
DE4042007A1 (de) 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
US5407928A (en) 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
DE4038128A1 (de) 1990-11-27 1992-06-04 Schering Ag 8-en-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
JPH0735335B2 (ja) * 1991-02-28 1995-04-19 五十嵐 正雄 子宮内膜症の治療薬
ZA929315B (en) 1991-12-20 1993-05-24 Akzo Nv 17-spirofuran-3'-ylidene steroids.
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
DE4216004B4 (de) 1992-05-12 2008-03-27 Bayer Schering Pharma Akiengesellschaft Verwendung kompetitiver Progesteronantagonisten
DE4216003A1 (de) 1992-05-12 1993-11-18 Schering Ag Dissoziierte kompetitive Progesteronantagonisten
US5684151A (en) 1992-07-01 1997-11-04 Ortho Pharmaceutical Corporation 1-arylsulphonyl, arylcarbonyl and 1-arylphosphonyl-3-phenyl-1,4,5,6-tetrahydropyridazines
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4434488A1 (de) 1994-09-14 1996-03-21 Schering Ag Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5576310A (en) 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
US5688810A (en) 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
WO1997041145A1 (en) 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO1998008471A1 (en) * 1996-08-30 1998-03-05 The Population Council, Inc. Vaginal application mifepristone
US5753655A (en) 1996-10-10 1998-05-19 Ortho Pharmaceutical Corporation 1-arylsulphonyl, arylcarbonyl and arylthiocarbonyl pyridazino derivatives and methods of preparation
DE19652408C2 (de) 1996-12-06 2002-04-18 Schering Ag Steroidester, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
DE19809845A1 (de) 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
US6172052B1 (en) * 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6740645B1 (en) * 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
UA74168C2 (uk) * 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
EP1328276B1 (en) * 2000-10-18 2005-11-23 Schering Aktiengesellschaft Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
CN1210079C (zh) * 2001-04-25 2005-07-13 上海市计划生育科学研究所 阴道环制剂及其应用
CN101080205B (zh) * 2004-07-09 2011-10-12 人口委员会股份有限公司 含孕酮受体调节剂的缓释组合物
CN1846703A (zh) * 2006-02-13 2006-10-18 程定超 米非司酮阴道给药制剂及其组成和制备方法
PL2148681T3 (pl) * 2007-04-20 2016-09-30 Selektywny modulator progesteronu w leczeniu krwawienia z macicy
DK2197415T3 (da) * 2007-09-20 2014-05-26 Lapidot Medical Imp And Marketing Ltd Sammensætninger og midler til at behandle uterusleiomyomer, leiomyom, myom, uterusfibroid, endometriose, adenomyose og beslægtede forstyrrelser med mifepriston
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids

Also Published As

Publication number Publication date
JP2013522361A (ja) 2013-06-13
CN107260746A (zh) 2017-10-20
WO2011119194A1 (en) 2011-09-29
KR20130009990A (ko) 2013-01-24
BR112012023281A2 (pt) 2016-05-17
SG10201504913UA (en) 2015-07-30
BR112013015509A2 (pt) 2016-09-13
SG183924A1 (en) 2012-10-30
ZA201207688B (en) 2013-07-31
NI201300059A (es) 2014-06-06
AU2017251837B2 (en) 2019-10-03
ECSP12012226A (es) 2012-11-30
CN102906103A (zh) 2013-01-30
KR20180104180A (ko) 2018-09-19
CR20120514A (es) 2013-02-11
EA201390959A1 (ru) 2013-11-29
EP2550288A1 (en) 2013-01-30
US20150203526A1 (en) 2015-07-23
KR102166867B1 (ko) 2020-10-19
CO6602170A2 (es) 2013-01-18
JP2018016655A (ja) 2018-02-01
AU2017251837A1 (en) 2017-11-16
IL255679A (en) 2018-01-31
AU2016200575A1 (en) 2016-02-18
JP2019123756A (ja) 2019-07-25
CN107260745A (zh) 2017-10-20
IL221820B (en) 2018-06-28
NI201200142A (es) 2013-04-12
MX2012010327A (es) 2012-11-16
US20190127413A1 (en) 2019-05-02
JP2016029083A (ja) 2016-03-03
US20130018027A1 (en) 2013-01-17
AU2010348967A1 (en) 2012-09-27
AU2016200575B2 (en) 2017-11-16
CL2012002544A1 (es) 2012-11-23
MY164622A (en) 2018-01-30
AU2010348967B2 (en) 2015-10-29
TW201200135A (en) 2012-01-01
NZ602525A (en) 2014-01-31
EP3865502A1 (en) 2021-08-18
UA110030C2 (uk) 2015-11-10
CA2793712A1 (en) 2011-09-29
AU2010348967C1 (en) 2016-04-28
JP5894143B2 (ja) 2016-03-23
SG10201510568WA (en) 2016-01-28
EA023743B1 (ru) 2016-07-29
AU2020200027A1 (en) 2020-01-30
TWI581797B (zh) 2017-05-11

Similar Documents

Publication Publication Date Title
AR080692A1 (es) Compuestos, composiciones y metodos para la administracion no toxica de antiprogestinas
AR108812A1 (es) Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo
PE20181045A1 (es) Compuestos utiles como inmunomoduladores
BR112017005767A2 (pt) composições de limpeza contendo uma polieteramina
JP2019514955A5 (es)
CY1120821T1 (el) Παραγωγα ταμοξιφαινης για θεραπεια νεοπλασματικων ασθενειων, ειδικα με υψηλο επιπεδο πρωτεϊνης her2
BR112017001599A2 (pt) ?sal de amônio quaternário, método para sua preparação, composições, método de melhoria do desempenho de um motor, uso de aditivo e método de preparação de uma composição combustível?.
BR112015026410A2 (pt) derivados de dolastatina 10 e auristatinas
CO6251243A2 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
BR112018013174A2 (pt) composição e método para crescimento de cabelo
AR086829A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR090993A1 (es) Pirazol indanil carboxamidas
BR112016026046A8 (pt) uso de compostos de tienotriazolodiazepina
RU2018113718A (ru) Новые соединения
BR112017013715A2 (pt) composição de líquido refrigerante, método de operação de motor de combustão interna usando a mesma, e uso da mesma
PE20141201A1 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
RU2016133471A (ru) Композиции и способы для лечения диабета и заболеваний печени
AR090618A1 (es) Proceso para la preparacion de inhibidores de sglt2 de derivados de bencilbenceno
WO2014186571A1 (en) Benzoxazole-based materials for vulcanization accelerator applications
BR112015017740A2 (pt) composto heterocíclico condensado
BR112016024238A2 (pt) uso de composições aquosas de redução de desvio
AR090323A1 (es) Imidazopiridazinas sustituidas, procesos e intermediarios para su obtencion y su uso en el tratamiento de enfermedades mediadas por la quinasa mps-1
AR105540A1 (es) Inhibidores de fucosidasas
AR109387A1 (es) INHIBIDORES DEL FACTOR XIa
BR112014030034A2 (pt) método para a estabilização de gesso beta semi-hidratado

Legal Events

Date Code Title Description
FB Suspension of granting procedure